776 related articles for article (PubMed ID: 30591990)
1. Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan.
Omboni S; Volpe M
Adv Ther; 2019 Feb; 36(2):278-297. PubMed ID: 30591990
[TBL] [Abstract][Full Text] [Related]
2. Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment.
Omboni S; Kario K; Bakris G; Parati G
J Hypertens; 2018 Apr; 36(4):720-733. PubMed ID: 29045341
[TBL] [Abstract][Full Text] [Related]
3. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
4. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
5. Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan.
Omboni S; Volpe M
Cardiovasc Ther; 2018 Dec; 36(6):e12471. PubMed ID: 30358114
[TBL] [Abstract][Full Text] [Related]
6. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
Powers B; Greene L; Balfe LM
J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101
[TBL] [Abstract][Full Text] [Related]
7. Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies.
Omboni S; Malacco E; Mallion JM; Fabrizzi P; Volpe M
High Blood Press Cardiovasc Prev; 2014 Mar; 21(1):1-19. PubMed ID: 24435506
[TBL] [Abstract][Full Text] [Related]
8. Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade.
Smith DH
Am J Hypertens; 2002 Oct; 15(10 Pt 2):108S-114S. PubMed ID: 12383591
[TBL] [Abstract][Full Text] [Related]
9. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.
Volpe M; Tocci G
Vasc Health Risk Manag; 2012; 8():371-80. PubMed ID: 22745561
[TBL] [Abstract][Full Text] [Related]
10. Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension.
Kato J; Yokota N; Tamaki N; Kariya S; Kita T; Ayabe T; Eto T; Kitamura K
Hypertens Res; 2011 Mar; 34(3):331-5. PubMed ID: 21124326
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
12. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.
Mason RP
Vasc Health Risk Manag; 2011; 7():405-16. PubMed ID: 21796255
[TBL] [Abstract][Full Text] [Related]
13. The Divergent Cardiovascular Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Myocardial Infarction and Death.
Strauss MH; Hall AS
Prog Cardiovasc Dis; 2016; 58(5):473-82. PubMed ID: 26586276
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study.
Ruilope LM; Schaefer A
Contemp Clin Trials; 2011 Sep; 32(5):710-6. PubMed ID: 21586342
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological interventions for hypertension in children.
Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD008117. PubMed ID: 24488616
[TBL] [Abstract][Full Text] [Related]
16. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
[TBL] [Abstract][Full Text] [Related]
17. The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis.
Pongpanich P; Pitakpaiboonkul P; Takkavatakarn K; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
Int Urol Nephrol; 2018 Dec; 50(12):2261-2278. PubMed ID: 30324578
[TBL] [Abstract][Full Text] [Related]
18. Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists.
Oparil S
J Hum Hypertens; 2002 May; 16 Suppl 2():S17-23. PubMed ID: 12035749
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological interventions for hypertension in children.
Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
[TBL] [Abstract][Full Text] [Related]
20. Antihypertensive drug use in resistant and nonresistant hypertension and in controlled and uncontrolled resistant hypertension.
de la Sierra A; Armario P; Oliveras A; Banegas JR; Gorostidi M; Vinyoles E; de la Cruz JJ; Segura J; Ruilope LM
J Hypertens; 2018 Jul; 36(7):1563-1570. PubMed ID: 29601411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
